By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company's website (https://expres2ionbio.com/meet-us-2/).

Progress in Vaccination Against Cancer (PIVAC-22), September 26-28, Torino, Italy
Meet ExpreS[2]ion's VP of Preclinical Development, Dr. Mette Thorn, and hear the company's preclinical development partners from the University of Bologna present on "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine," in a forum covering the most recent advances in the field of cancer immunotherapy. More information and registration can be found on the PIVAC-22 website (https://www.pivac22.it/).

Aktiedagen Lund, September 26 at 11:00 CET, Virtual
Join CEO of ExpreS[2]ion Biotechnologies Bent U. Frandsen for a live update at Aktiedagen in Lund. You can stream the event live or on demand via Aktiespararnas YouTube Channel (https://www.youtube.com/c/AktiespararnaEvent/) or at Aktiespararna.se/tv/live.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se